AndréT., ColinP., LouvetC.: Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer. Results of a randomized trial. J Clin Oncol, 21: 2896–2903, 2003.
2.
AndréT., BoniC., Mounedji-BoudiafL.: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350: 2343–2351, 2004.
3.
SaltzL.B., NiedzwieckiD., HollisD.: Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone in stage III colon cancer (intergroup trial CALGB C89803). Proc ASCO, 22: A3500, 2004.
4.
Van CutsemE., LabiancaR., HossfeldG.: Randomized phase III trial comparing infused irinotecan/5-fluorouracil/folinic acid versus 5FU/FA in stage III colon cancer patients (PETACC-3). Proc ASCO, 23: LBA8, 2005.
5.
RothenbergM.L., MeropolN.J., PoplinE.A.: Mortality associated with irinotecan plus 5FULV: summary findings of an independent panel. J Clin Oncol, 19: 3801–3807, 2001.
6.
YchouM., RaoulJ.L., DouillardJ.Y.: A phase III randomized trial of LV5FU2 + CPT11 vs LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord 02/FFCD9802). Proc ASCO, 23: A3502, 2005.
7.
DeGramontA., BoniC., NavarroJ.: Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and III colon cancer: efficacy results with a median follow-up of 4 years. Proc ASCO, 23: A3501, 2005.
8.
WolmarkN., WieandJ.P., KueblerL.: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. Proc ASCO, 23: A3500, 2005.
9.
SchmollH.J., TaberneroJ., NowackiM.: Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs bolus 5FU/LV as adjuvant therapy for pts with stage III colon cancer. Proc ASCO, 23: A3523, 2005.
10.
GrayR.G., BarnwellJ., HillsR.: QUASAR: a randomized study of adjuvant chemoterapy vs observation including 3238 colorectal cancer pts. Proc ASCO, 22: A3501, 2004.
11.
Meta-analysis of randomized trials testing the biochemical modulation of 5FU by methotrexate in metastatic colorectal cancer.Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol, 12: 960–969, 1994.
12.
KohneC.H., WilsJ., LorenzM.: Randomized phase III trial of high-dose 5FU given as a weekly 24-hour infusion with or without leucovorin vs bolus 5FU plus leucovorin in advanced colorectal cancer. EORTC 40952. J Clin Oncol, 21: 3721–3728, 2003.
13.
DouillardJ.Y., CunninghamD., RothA.D.: Irinotecan combined with 5FU compared with 5FU alone as first line treatment for metastatic colorectal cancer: a multicentric randomised trial. Lancet, 355: 1041–1047, 2000.
14.
SaltzL.B., CoxJ.V., BlankeC.: Irinotecan plus 5FU and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Eng J Med, 343: 905, 2000.
15.
De GramontA., FigerA., SeymourM.: Leucovorin and 5FU with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol, 18: 2938, 2000.
16.
GoldbergR.M., SargentD.J., MortonR.F.: A randomised controlled trial of 5FU plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 22: 23–30, 2004.
17.
TournigandC., AndréT., AchilleE.: FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 22: 229–237, 2004.
18.
HurwitzH., FehrenbacherL., NovotnyW.: Bevacizumab plus irinotecan, 5FU and leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335–2342, 2004.
19.
CunninghamD., HumbletY., SienaS.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351: 337–345, 2004.
20.
ArkenauH.T., SchmollH., KubickaS.: Infusional FUFOX versus CAPOX as first line treatment of metastatic colorectal cancer: results of the safety and efficacy analysis. Proc ASCO, 23: A3507, 2005.
21.
Seymour MT for the UK NCRI Colorectal Clinical Studies Group:Fluorouracil, oxaliplatin and CPT11 use and sequencing (MRC FOCUS): a 2135 patient randomized trial in advanced colorectal cancer. Proc ASCO, 23: A3518, 2005.
22.
PitotH.C., RowlandK.M., SargentD.J.: N9841: a randomized phase III equivalence trial of irinotecan versus oxaliplatin/5FU/leucovorin (FOLFOX4) in patients with advanced colorectal cancer previously treated with 5FU. Proc ASCO, 23: A3506, 2005.
23.
PluzanskaA., MainwaringP., CassidyJ.: Final results of a randomized phase III study evaluating the addition of oxaliplatin first line to 5FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study). Proc ASCO, 23: A3517, 2005.
24.
HochsterH.S., WellesL., HartL.: Safety and efficacy of bevacizumab when added to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer: TREE 1 and 2 studies. Proc ASCO, 23: A3515, 2005.
25.
Diaz RubioE., TaberneroJ., van CutsemE.: Cetuximab in combination with FOLFOX4 in the first line treatment in patients with EGFR expressing metastatic colorectal cancer: an international phase II study. Proc ASCO, 23: A3535, 2005.
26.
GiantonioB.J., CatalanoP.J., MeropolN.J.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO, 23: A2, 2005.
